A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $204 to $227
AbbVie Is Maintained at Buy by Guggenheim
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), AbbVie (ABBV) and Molecular Partners (MOLN)
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $205
AbbVie Analyst Ratings
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $250
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and AbbVie (ABBV)
Raymond James Adjusts Price Target on AbbVie to $227 From $220, Maintains Outperform Rating
TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $250
William Blair Initiates AbbVie(ABBV.US) With Buy Rating
AbbVie's Strong Financial Performance and Growth Potential Justifies Buy Rating
Cantor Fitzgerald Maintains AbbVie(ABBV.US) With Buy Rating, Cuts Target Price to $210
AbbVie's Strategic Acquisitions and Strong Financial Outlook Justify Buy Rating
Bernstein Maintains AbbVie(ABBV.US) With Hold Rating, Maintains Target Price $203
AbbVie (ABBV) Has a New Rating From Scotiabank
Cantor Fitzgerald Initiates Coverage On AbbVie With Overweight Rating, Announces Price Target of $210
AbbVie Analyst Ratings
BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Cuts Target Price to $200
Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $214
AbbVie Analyst Ratings